The Aurora kinase B relocation blocker LXY18 triggers mitotic catastrophe selectively in malignant cells
PLOS ONE · 2023
DOI: 10.1371/journal.pone.0293283 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Julia Kalashova und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Discovery Oncology, Chengdu Anticancer Bioscience, Chengdu, Sichuan, China. Hauptthemen laut MEDLINE: Aurora Kinase A, Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The J. Michael Bishop Institute of Cancer Research receives funding through an endowment from Anticancer Bioscience, a company actively engaged in the commerci….
Abstract (Originalsprache)
The mitotic regulator, Aurora kinase B (AURKB), is frequently overexpressed in malignancy and is a target for therapeutic intervention. The compound, LXY18, is a potent, orally available small molecule that inhibits the proper localization of AURKB during late mitosis, without affecting its kinase activity. In this study, we demonstrate that LXY18 elicits apoptosis in cancer cells derived from various indications, but not in non-transformed cell lines. The apoptosis is p53-independent, triggered by a prolonged mitotic arrest and occurs predominantly in mitosis. Some additional cells succumb post-mitotic slippage. We also demonstrate that cancer cell lines refractory to AURKB kinase inhibitors are sensitive to LXY18. The mitotic proteins MKLP2, NEK6, NEK7 and NEK9 are known regulators of AURKB localization during the onset of anaphase. LXY18 fails to inhibit the catalytic activity of these AURKB localization factors. Overall, our findings suggest a novel activity for LXY18 that produces a prolonged mitotic arrest and lethality in cancer cells, leaving non-transformed cells healthy. This new activity suggests that the compound may be a promising drug candidate for cancer treatment and that it can also be used as a tool compound to further dissect the regulatory network controlling AURKB localization.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Discovery Oncology, Chengdu Anticancer Bioscience, Chengdu, Sichuan, China.
- Department of Basic Cancer Research, J. Michael Bishop Institute of Cancer Research, Chengdu, Sichuan, China.
ORCID-Profile: Thaddeus D Allen
Förderung
- The J. Michael Bishop Institute of Cancer Research receives funding through an endowment from Anticancer Bioscience, a company actively engaged in the commerci…
Zitieren
APA
Kalashova, J., Yang, C., Li, H., Long, Y., Yu, D., Zhang, T., Liu, X., Choudhry, N., Shi, Q., & Allen, T. D. (2023). The Aurora kinase B relocation blocker LXY18 triggers mitotic catastrophe selectively in malignant cells. PLOS ONE. https://doi.org/10.1371/journal.pone.0293283
Vancouver
Kalashova J, Yang C, Li H, Long Y, Yu D, Zhang T, et al. The Aurora kinase B relocation blocker LXY18 triggers mitotic catastrophe selectively in malignant cells. PLOS ONE. 2023. doi:10.1371/journal.pone.0293283
BibTeX
@article{Kalashova2023,
author = {Kalashova, Julia and Yang, Chenglu and Li, Hongmei and Long, Yan and Yu, Duo and Zhang, Ting and Liu, Xumei and Choudhry, Namrta and Shi, Qiong and Allen, Thaddeus D},
title = {The Aurora kinase B relocation blocker LXY18 triggers mitotic catastrophe selectively in malignant cells},
journal = {PLOS ONE},
year = {2023},
doi = {10.1371/journal.pone.0293283}
}
EUVIMED